Ubs Oconnor LLC Affimed N.V. Transaction History

Ubs Oconnor LLC

  • $1.46 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$0.32 - $0.62 $180,818 - $350,335
-565,057 Reduced 68.91%
254,943 $158,000
Q3 2023

Nov 14, 2023
BUY
$0.46 - $0.65 $220,386 - $311,415
479,100 Added 140.54%
820,000 $393,000
Q2 2023

Aug 14, 2023
BUY
$0.57 - $1.08 $194,312 - $368,172
340,900 New
340,900 $204 Million

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email